
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
Catch up on the hematology headlines you missed in March 2026.
Recent updates in hematology underscore simultaneous progress in therapeutic innovation, precision diagnostics, and efforts to standardize care across rare and complex blood disorders.






